BioNTech SE ADR (BNTX): Price and Financial Metrics


BioNTech SE ADR (BNTX): $161.66

-7.57 (-4.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BNTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 462

in industry

BNTX POWR Grades


  • Value is the dimension where BNTX ranks best; there it ranks ahead of 95.07% of US stocks.
  • The strongest trend for BNTX is in Momentum, which has been heading down over the past 160 days.
  • BNTX ranks lowest in Momentum; there it ranks in the 4th percentile.

BNTX Stock Summary

  • With a year-over-year growth in debt of 387.96%, BioNTech SE's debt growth rate surpasses 96.91% of about US stocks.
  • Over the past twelve months, BNTX has reported earnings growth of -2,945.62%, putting it ahead of merely 0.63% of US stocks in our set.
  • Revenue growth over the past 12 months for BioNTech SE comes in at 8,157.54%, a number that bests 99.78% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to BNTX, based on their financial statements, market capitalization, and price volatility, are QURE, MRNS, MRNA, LBRDA, and MICT.
  • BNTX's SEC filings can be seen here. And to visit BioNTech SE's official web site, go to www.biontech.de.

BNTX Stock Price Chart Interactive Chart >

Price chart for BNTX

BNTX Price/Volume Stats

Current price $161.66 52-week high $464.00
Prev. close $169.23 52-week low $90.29
Day low $160.60 Volume 3,528,300
Day high $175.72 Avg. volume 2,982,650
50-day MA $263.31 Dividend yield N/A
200-day MA $259.47 Market Cap 39.21B

BioNTech SE ADR (BNTX) Company Bio


BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders.


BNTX Latest News Stream


Event/Time News Detail
Loading, please wait...

BNTX Latest Social Stream


Loading social stream, please wait...

View Full BNTX Social Stream

Latest BNTX News From Around the Web

Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.

BioNTech down 9% following Israeli fourth COVID jab study on Omicron

Shares of BioNTech (BNTX -7.8%) have fallen this morning following results from an Israeli study showing that a fourth COVID-19 shot is less effective against the Omicron variant than prior strains. "We see an increase in antibodies, higher than after the third dose," said lead researcher Gili Regev-Yochay. "However, we see...

Seeking Alpha | January 18, 2022

This New Study Suggests Pfizer, BioNTech Are Losing The Omicron Battle

A fourth dose of Pfizer and BioNTech''s Covid shot is only partly effective against omicron, according to a new test. The vaccine stocks fell.

Investor''s Business Daily | January 18, 2022

Why Moderna, Pfizer, BioNTech And Novavax Shares Are Falling Today

Shares of vaccine makers, including Moderna Inc Full story available on Benzinga.com

Benzinga | January 18, 2022

The Right Bet On BioNTech SE

No summary available.

Seeking Alpha | January 18, 2022

Omicron: Why a fourth dose of coronavirus vaccines may not be 'absolutely necessary,' doctor says

Dr. Robert G. Lahita MD, PhD, Director of the Institute for Autoimmune and Rheumatic Disease at Saint Joseph Health and author of Immunity Strong, joins Yahoo Finance Live to discuss the latest information on COVID-19 booster vaccinations, transmissibility, and the pressures felt by hospitals in remote regions.

Yahoo | January 18, 2022

Read More 'BNTX' Stories Here

BNTX Price Returns

1-mo -41.26%
3-mo -43.55%
6-mo -42.67%
1-year 54.40%
3-year N/A
5-year N/A
YTD -37.29%
2021 216.24%
2020 140.61%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8547 seconds.